礼来加入免疫原的大型制药合作伙伴名单

Pharmadeals Review Pub Date : 2012-06-01 DOI:10.3833/pdr.v2012i1.1648

Heather Cartwright

{"title":"礼来加入免疫原的大型制药合作伙伴名单","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i1.1648","DOIUrl":null,"url":null,"abstract":"Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i1.1648\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i1.1648\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i1.1648","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

礼来公司已获得使用ImmunoGen公司的美坦素类靶向抗体有效载荷(TAP)技术的权利，以开发特定数量的抗体-药物偶联物，用于潜在的癌症治疗。ImmunoGen将获得2000万美元的预付款，并可能获得高达2亿美元的里程碑付款，用于获得每个许可，以及任何最终产品的销售特许权使用费。通过这笔交易，礼来公司加入了ImmunoGen的TAP合作伙伴名单，包括安进、拜耳医疗、罗氏、诺华和赛诺菲。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators

Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量